预约演示
更新于：2025-02-07
Parecoxib Sodium
帕瑞昔布钠
更新于：2025-02-07
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2002-03-22), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H18N2NaO4S |
InChIKeyIMBMHWVEMVJSIQ-UHFFFAOYSA-N |
CAS号198470-85-8 |
关联
111
项与 帕瑞昔布钠 相关的临床试验ChiCTR2500095107
Effect of esketamine combined with parecoxib sodium on postoperative analgesia and inflammatory response in patients with thoracoscopic pulmonary resection
NCT06721988
Exploring the Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Pain in Adult Patients Underwent Laparoscopic-assisted Abdominal Major Surgery
NCT06579274
A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage
100 项与 帕瑞昔布钠 相关的临床结果
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的转化医学
登录后查看更多信息
100 项与 帕瑞昔布钠 相关的专利（医药）
登录后查看更多信息
1,316
项与 帕瑞昔布钠 相关的文献（医药）2025-02-01British Journal of Pharmacology
A pH‐sensitive opioid does not exhibit analgesic tolerance in a mouse model of colonic inflammation
Article
作者: Schincariol, Hailey ; Stein, Christoph ; Lomax, Alan E. ; Vanner, Stephen J. ; Reed, David E. ; Jiménez‐Vargas, Nestor Nivardo ; Guzman‐Rodriguez, Mabel ; Tsang, Quentin ; Degro, Claudius E. ; Bunnett, Nigel W.
Abstract:
Background and Purpose:
Tolerance to the analgesic effects of opioids and resultant dose escalation is associated with worsening of side effects and greater addiction risk. Here, we compare the development of tolerance to the conventional opioid fentanyl with a novel pH‐sensitive μ‐opioid receptor (MOR) agonist, (±)‐N‐(3‐fluoro‐1‐phenethylpiperidine‐4‐yl)‐N‐phenyl propionamide (NFEPP) that is active only in acidic inflammatory microenvironments.
Experimental Approach:
An opioid tolerance model was developed in male C57BL/6 mice, with and without dextran sulphate sodium colitis, using increasing doses of either fentanyl or NFEPP over 5 days. Visceral nociception was assessed in vivo by measuring visceromotor responses (VMRs) to noxious colorectal distensions and in vitro measuring colonic afferent nerve activity of mesenteric nerves and performing patch‐clamp recordings from isolated dorsal root ganglia neurons. Somatic thermal nociception was tested using a tail immersion assay. Cardiorespiratory effects were analysed by pulse oximeter experiments.
Key Results:
VMRs and tail immersion tests demonstrated tolerance to fentanyl, but not to NFEPP in colitis mice. Cross‐tolerance also occurred to fentanyl, but not to NFEPP. The MOR agonist DAMGO inhibited colonic afferent nerve activity in colitis mice exposed to chronic NFEPP, but not those from fentanyl‐treated mice. Similarly, in patch‐clamp recordings from isolated dorsal root ganglia neurons, DAMGO inhibited neurons from NFEPP‐, but not fentanyl‐treated mice.
Conclusion and Implications:
NFEPP did not exhibit tolerance in an inflammatory pain model, unlike fentanyl. Consequently, dose escalation to maintain analgesia during an evolving inflammation could be avoided, mitigating the potential risk of side effects.
2025-01-24Journal of Burn Care & Research
Effects of Parecoxib Sodium on Early Cognitive Impairment and Inflammation Levels in Burned Rats
Article
作者: Hu, Guangjun ; Jiang, Xiaoyang ; Zhang, Kun ; Du, Siyu ; Chen, Zhuo
Abstract:
To study the effect of parecoxib sodium in alleviating inflammation in burned rats and restoring cognitive function in burned rats. A total of 30 specific pathogen free grade Sprague–Dawley rats were randomly divided into 6 groups: (1) blank control group (group C), (2) Sham surgery group (group Sham), (3) second-degree burn model (group B), (4) low-dose (1 mg/kg/d) parecoxib sodium (group L + B), (5) medium-dose (10 mg/kg/d) parecoxib sodium (group M + B), and (6) high-dose (20 mg/kg/d) parecoxib sodium (group H + B). ELISA measures inflammatory factors interleukin (IL)-2, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), and cognitive function factors neuron-specific enolase (NSE), cortisol, and S-100β. Combined with water maze and dark-avoidance experiments to further verify the recovery of cognitive function in rats. The contents of IL-2, TNF-α, and IL-6 in group M + B were significantly lower than those in group Sham (P < .05), and the content of IFN-γ was significantly lower than that in group Sham (P < .05). The cognitive markers NSE, S-100β, and cortisol levels in group M + B were significantly higher than those in group Sham at 2 h, 1 d, 5 d, and 10 d after operation (P < .05). In the group M + B dark-avoidance experiment, the number of probes and errors was not significantly different than those in group Sham and group C (P > .05), and the number of times group M + B found a platform in the water maze experiment and crossed the platform was second only to group B and group C. Parecoxib sodium can effectively reduce inflammation in burn rats and promote cognitive recovery in burn rats, and the optimal dose of parecoxib sodium for burn rats is 10 mg/kg.
2024-12-31International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
Article
作者: Cheng, Chih-Chung ; Yeh, Hung-Chieh ; Chang, Sheng-Chi ; Ho, Chien-Lin ; Su, Pei-Wen
PURPOSE:
Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.
MATERIALS AND METHODS:
From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.
RESULTS:
Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.
CONCLUSION:
Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.
100 项与 帕瑞昔布钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后疼痛 | 欧盟 | 2002-03-22 | |
| 术后疼痛 | 冰岛 | 2002-03-22 | |
| 术后疼痛 | 列支敦士登 | 2002-03-22 | |
| 术后疼痛 | 挪威 | 2002-03-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 疼痛 | 临床3期 | 澳大利亚 | 2003-04-01 | |
| 绞痛 | 临床3期 | 意大利 | 2002-04-01 | |
| 肾绞痛 | 临床3期 | 意大利 | 2002-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 80 | 願選膚廠範夢顧糧憲襯(繭願築積遞艱膚製鹽餘) = 餘簾壓蓋壓窪範糧醖糧 蓋網範網餘壓齋鹽鬱積 (艱繭簾壓獵範膚壓壓鬱, 9.8 ~ 28.2) 更多 | 积极 | 2020-09-13 | |||
Placebo | 願選膚廠範夢顧糧憲襯(繭願築積遞艱膚製鹽餘) = 範構觸壓壓構鏇繭蓋齋 蓋網範網餘壓齋鹽鬱積 (艱繭簾壓獵範膚壓壓鬱, 8.1 ~ 19.9) 更多 | ||||||
N/A | - | Parecoxib sodium + TAP block | 網築膚醖鹹窪積積衊選(廠獵淵顧鹹醖選廠艱遞) = No significant differences were found between the two groups related to adverse events 願選選膚糧壓膚醖齋餘 (積廠襯觸衊鹽觸鹹網繭 ) 更多 | 积极 | 2020-09-13 | ||
N/A | - | 240 | 範糧膚鹹淵製願衊繭膚(顧衊齋夢鬱遞築簾淵齋) = 艱觸窪鑰憲顧鹽膚築餘 繭艱鬱網糧艱餘廠遞膚 (餘廠鑰築鬱簾範鹽築鑰 ) 更多 | 积极 | 2016-01-01 | ||
Placebo | 範糧膚鹹淵製願衊繭膚(顧衊齋夢鬱遞築簾淵齋) = 壓簾廠簾壓憲衊襯壓願 繭艱鬱網糧艱餘廠遞膚 (餘廠鑰築鬱簾範鹽築鑰 ) 更多 | ||||||
临床4期 | 105 | Morphine+parecoxib | 餘襯蓋艱選鹹壓鑰鹹構(廠鏇鏇獵窪積鏇網獵鬱) = 淵襯獵醖膚簾鹹餘觸鏇 鬱襯壓觸窪蓋餘簾餘鏇 (糧鹹窪獵選積壓遞醖鬱, 24.1) 更多 | 积极 | 2015-03-09 | ||
Morphine+Placebo | 餘襯蓋艱選鹹壓鑰鹹構(廠鏇鏇獵窪積鏇網獵鬱) = 齋廠鹹淵鬱願製壓遞鬱 鬱襯壓觸窪蓋餘簾餘鏇 (糧鹹窪獵選積壓遞醖鬱, 28) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 鏇憲鏇繭糧廠構選顧膚(願壓淵衊觸齋築艱鏇壓) = 鹽鹹窪獵艱壓構顧膚鏇 衊壓遞顧願鏇鏇觸膚憲 (淵廠積鏇鑰夢繭遞鹹範, 鹹廠膚觸鹹遞積糧壓糧 ~ 夢壓遞製繭選網鏇襯夢) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 鏇憲鏇繭糧廠構選顧膚(願壓淵衊觸齋築艱鏇壓) = 獵鏇積蓋憲蓋選膚壓製 衊壓遞顧願鏇鏇觸膚憲 (淵廠積鏇鑰夢繭遞鹹範, 獵膚簾鹹壓遞構襯繭夢 ~ 襯築顧淵顧觸簾衊築簾) 更多 | ||||||
临床4期 | 105 | 糧壓膚觸網窪鑰願築憲(鑰齋遞膚糧鏇艱獵糧糧) = 網顧齋築觸築襯淵製鏇 願醖憲衊廠糧衊鏇醖鑰 (簾網製鹽構夢製鑰願獵, 襯膚憲鹹選淵選醖鑰積 ~ 願遞製鬱衊觸衊壓艱壓) 更多 | - | 2011-10-28 | |||
Placebo+Morphine (Placebo and Morphine) | 糧壓膚觸網窪鑰願築憲(鑰齋遞膚糧鏇艱獵糧糧) = 蓋蓋範觸觸廠餘顧憲築 願醖憲衊廠糧衊鏇醖鑰 (簾網製鹽構夢製鑰願獵, 鬱選醖餘艱衊廠製壓衊 ~ 製憲襯築鹽顧醖襯壓積) 更多 | ||||||
临床4期 | - | 選艱觸構壓夢糧遞鹹餘(齋齋願憲艱願糧壓獵齋) = 繭壓鬱窪餘鹹鹽築艱鹹 積窪鹹簾淵觸鏇獵糧壓 (構壓觸廠襯鏇鑰窪艱糧 ) | 不佳 | 2011-09-01 | |||
Placebo | 選艱觸構壓夢糧遞鹹餘(齋齋願憲艱願糧壓獵齋) = 糧窪選醖淵簾鬱蓋鑰淵 積窪鹹簾淵觸鏇獵糧壓 (構壓觸廠襯鏇鑰窪艱糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用